Efficacy and safety of erenumab in participants with episodic migraine who have had 2-4 prior preventive treatment failures

According to a recent study, erenumab (140 mg) demonstrated long-lasting effectiveness over a period of 3 years in individuals with episodic migraine (EM) who had 2-4 unsuccessful attempts at preventive treatment. This study’s findings were published in the journal, Neurology.

Following the 12-week double-blind treatment phase (DBTP) of the LIBERTY study, 240/246 (97.6%) participants entered the Open-Label Extension Phase (OLEP) and received a monthly dosage of 140 mg of erenumab for a period of 3 years. The main outcomes of this study included determining the percentage of participants who achieved a reduction of 50% or more in monthly migraine days (MMDs), analyzing the mean change in MMDs from the baseline, and assessing the tolerability and safety of the treatment.

At week 168, a total of 79 out of 151 participants (52.3%) in the overall population, who had valid data points, achieved a reduction of at least 50% in MMDs and were considered responders. In the continuous erenumab group, 35 out of 117 participants (29.9%) were ≥50% responders at week 12 of the double-blind treatment period, and 26 out of 35 (74.3%) remained responders in at least half of the visits during the open-label extension period. Among the 82 out of 117 participants (70.1%) in the continuous erenumab group who did not achieve responder status at week 12, 17 out of 82 (20.7%) converted to ≥50% responders in at least half of the open-label extension phase visits. In the placebo-erenumab group, out of the 103 out of 120 participants (85.8%) who did not achieve responder status at week 12, 42 out of 103 (40.8%) converted to ≥50% responders in at least half of the open-label extension phase visits after switching to erenumab treatment. The mean (SD) change in MMD from baseline over 3 years showed a sustained improvement of -4.4 [3.9] days at week 168. The safety and tolerability profile remained consistent with previous studies.

The above study demonstrated that in individuals with episodic migraine (EM) who had previously encountered 2-4 unsuccessful preventive treatment attempts experienced long-lasting efficacy with erenumab (140 mg) over a period of 3 years.